Importance of patient selection when determining the significance of the CYP3A5 polymorphism in clinical trials

Pharmacogenomics Journal

Volumn 4, Issue 6, 2004, Pages 362-364

  Foti, R S ^a   Fisher, Michael B ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIESTROGEN; AZATHIOPRINE; BENZODIAZEPINE DERIVATIVE; BENZOTHIAZEPINE DERIVATIVE; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450 3A1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DILTIAZEM; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN 1; NAVELBINE; NIFEDIPINE; RAPAMYCIN; TACROLIMUS; TAMOXIFEN; TRIAZOLAM;

AFRICAN AMERICAN; ARTICLE; BREAST CANCER; CAUCASIAN; DOSE RESPONSE; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME SUBSTRATE; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; PATIENT SELECTION; POPULATION GENETICS; PRIORITY JOURNAL;

CLINICAL TRIALS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; PATIENT SELECTION; POLYMORPHISM, GENETIC;

EID: 10044284087     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500286     Document Type: Article

References (14)

1. Williams JA et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 2002; 30: 883-891.
2. Williams JA et al. A significant drug-metabolizing role for CYP3A5? Drug Metab Dispos 2003; 31: 1526-1530.
3. Wong M et al. The cytochrome P450 (CYP) 3A5 3 single nucleoticle polymorphism (SNP) and chemotherapy dosage determination. From Cell to Society Research Conference 2002; Poster 17-12 ( http://www.chs.usyd.edu.au/conf2002/minipost/bt-wong.pdf).
4. Fukuda T et al. CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers. Pharmacogenomics J 2004; 4: 34-39.
5. Thummel KE. Does the CYP3A5 3 polymorphism affect in vivo drug elimination? Pharmacogenetics 2003; 13: 585-587.
6. Shih PS, Huang JD. Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with difference CYP3A5 genotypes. Drug Metab Dispos 2002; 30: 1491-1496.
7. Kuehl P et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-391.
8. Klag MJ et al. End-stage renal disease in African American and white men. 16-year MRFIT findings. JAMA 1997; 277 1293-1298.
9. Johnson LB. Some of the challenges of encouraging organ donation among minority populations. NC Med J 2004; 65: 35-36.
10. Thervet E et al. Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentrations-to-close ratio in renal transplant recipients. Transplantation 2003; 76 1233-1235.
11. Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Clin Transplant 1998; 65: 515-523.
12. Hesselink DA et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the clacineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-254.
13. Floyd MD et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African American men and women. Pharmacogenetics 2003; 13: 595-606.
14. Lamba JK et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002; 12: 121-132.